BRPI0618490A2 - método de diagnóstico ou de prognóstico de doença hepática, assim como procedimento de crivação ou de detecção de compostos destinados à prevenção ou ao tratamento de doenças hepáticas - Google Patents

método de diagnóstico ou de prognóstico de doença hepática, assim como procedimento de crivação ou de detecção de compostos destinados à prevenção ou ao tratamento de doenças hepáticas Download PDF

Info

Publication number
BRPI0618490A2
BRPI0618490A2 BRPI0618490-1A BRPI0618490A BRPI0618490A2 BR PI0618490 A2 BRPI0618490 A2 BR PI0618490A2 BR PI0618490 A BRPI0618490 A BR PI0618490A BR PI0618490 A2 BRPI0618490 A2 BR PI0618490A2
Authority
BR
Brazil
Prior art keywords
liver disease
compounds
treatment
screening
prevention
Prior art date
Application number
BRPI0618490-1A
Other languages
English (en)
Inventor
Pierre Casellas
Hubert Vidal
Isabelle Buisson
Jean Marchand
Dominique Simon
Sylvaine Galiegue
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0618490A2 publication Critical patent/BRPI0618490A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODO DE DIAGNóSTICO OU DE PROGNóSTICO DE DOENçA HEPáTICA, ASSIM COMO PROCEDIMENTO DE CRIVAçãO OU DE DETECçãO DE COMPOSTOS DESTINADOS à PREVENçãO OU AO TRATAMENTO DE DOENçAS HEPáTICAS. O presente pedido tem por objeto um método de diagnóstico de doenças hepáticas, compreendendo a medida da expressão da apolipoproteina A4 nas células ou nos tecidos hepáticos e na circulação (sangue, plasma, soro). Ele é além disso relativo a um procedimento de crivação de moléculas para o tratamento dessas doenças colocada em contato desses compostos com um mamífero e medida da expressão da apolipoproteina A4 nessas células de origem hepática ou na circulação desse mamífero.
BRPI0618490-1A 2005-11-10 2006-11-10 método de diagnóstico ou de prognóstico de doença hepática, assim como procedimento de crivação ou de detecção de compostos destinados à prevenção ou ao tratamento de doenças hepáticas BRPI0618490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0511432A FR2893136A1 (fr) 2005-11-10 2005-11-10 Procedes de diagnostic de maladies hepatiques et de criblage de molecules pour le traitement de ces maladies
PCT/FR2006/002503 WO2007057548A2 (fr) 2005-11-10 2006-11-10 Procedes de diagnostic de maladies hepatiques et de criblage de molecules pour le traitement de ces maladies

Publications (1)

Publication Number Publication Date
BRPI0618490A2 true BRPI0618490A2 (pt) 2011-08-30

Family

ID=36972931

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618490-1A BRPI0618490A2 (pt) 2005-11-10 2006-11-10 método de diagnóstico ou de prognóstico de doença hepática, assim como procedimento de crivação ou de detecção de compostos destinados à prevenção ou ao tratamento de doenças hepáticas

Country Status (13)

Country Link
US (1) US20090220958A1 (pt)
EP (1) EP1949110A2 (pt)
JP (1) JP2009515514A (pt)
KR (1) KR20080074121A (pt)
CN (1) CN101310187A (pt)
AR (1) AR058510A1 (pt)
AU (1) AU2006314369A1 (pt)
BR (1) BRPI0618490A2 (pt)
CA (1) CA2627082A1 (pt)
FR (1) FR2893136A1 (pt)
RU (1) RU2008123385A (pt)
TW (1) TW200804811A (pt)
WO (1) WO2007057548A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257814B1 (en) * 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
US20110256561A1 (en) * 2008-12-24 2011-10-20 The University Of Tokyo Liver disease marker, method and apparatus for measuring the same, and method for assaying pharmaceutical preparation
MX2015004844A (es) * 2012-10-17 2015-11-16 Enterome Firmas geneticas de trastornos inflamatorios que se relacionan con el higado.
JPWO2019167874A1 (ja) 2018-02-27 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ａｐｏａ４に対するモノクローナル抗体、免疫学的測定方法及び測定用キット
CN113018459A (zh) * 2021-03-09 2021-06-25 百码科技(深圳)有限公司 一种基因治疗减肥的生物药剂及其制备方法
CN112891561A (zh) * 2021-03-09 2021-06-04 百码科技(深圳)有限公司 一种基因治疗脂肪肝的生物药剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
AU2001251245A1 (en) * 2000-04-05 2001-10-23 Genaissance Pharmaceuticals, Inc. Haplotypes of the apoa4 gene
US6727066B2 (en) * 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
WO2004058966A1 (ja) * 2002-12-24 2004-07-15 Nitto Boseki Co., Ltd. 肝臓疾患診断用マーカー蛋白質およびそれを利用した肝臓疾患診断方法

Also Published As

Publication number Publication date
WO2007057548A3 (fr) 2007-07-26
RU2008123385A (ru) 2009-12-20
WO2007057548A2 (fr) 2007-05-24
FR2893136A1 (fr) 2007-05-11
EP1949110A2 (fr) 2008-07-30
CA2627082A1 (fr) 2007-05-24
AU2006314369A1 (en) 2007-05-24
CN101310187A (zh) 2008-11-19
US20090220958A1 (en) 2009-09-03
AR058510A1 (es) 2008-02-06
KR20080074121A (ko) 2008-08-12
TW200804811A (en) 2008-01-16
JP2009515514A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
Ruiz-Hernandez et al. Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence
BRPI0618490A2 (pt) método de diagnóstico ou de prognóstico de doença hepática, assim como procedimento de crivação ou de detecção de compostos destinados à prevenção ou ao tratamento de doenças hepáticas
Peter et al. Plasma free H2S levels are elevated in patients with cardiovascular disease
BR112012026239A2 (pt) polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk
Suominen et al. Determination of serotonin and dopamine metabolites in human brain microdialysis and cerebrospinal fluid samples by UPLC-MS/MS: discovery of intact glucuronide and sulfate conjugates
Alfaras et al. Health benefits of late-onset metformin treatment every other week in mice
Boonla et al. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis
Jenkinson et al. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer
Stein et al. Autism and phthalate metabolite glucuronidation
Naguib et al. Serum level of the autophagy biomarker Beclin-1 in patients with diabetic kidney disease
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
Navaneethan et al. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study
Tang et al. Elevated CpG island methylation of GCK gene predicts the risk of type 2 diabetes in Chinese males
BR112013006528A2 (pt) fosfolipidoma de câncer
Şen et al. Serum prolidase activity and oxidant–antioxidant status in children with chronic hepatitis B virus infection
Poljak et al. Quantitative proteomics of delirium cerebrospinal fluid
Hillenbrand et al. Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors
Mastrodonato et al. High-fat diet alters the oligosaccharide chains of colon mucins in mice
Jain et al. Salivary proteome patterns of individuals exposed to High Altitude
ES2772701T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras de esputo
Gu et al. Clinical application of metabolomics in pancreatic diseases: A mini-review
BR112014014843A2 (pt) método para detecção de mutações kras
Sinha et al. Proteomics in clinical interventions: achievements and limitations in biomarker development
Bolling et al. Microsomal quercetin glucuronidation in rat small intestine depends on age and segment
San-Cristobal et al. Gene methylation parallelisms between peripheral blood cells and oral mucosa samples in relation to overweight

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.